Levobunolol (hydrochloride)

Levobunolol (l-Bunolol) hydrochloride is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol hydrochloride is an ocular hypotensive agent and lowers mean intraocular pressure (IOP) . Levobunolol hydrochloride can be used for glaucoma and superior oblique myokymia (SOM) research[1][2][3].

Product Specifications

CAS Number

[27912-14-7]

Product Name Alternative

L-Bunolol hydrochloride

UNSPSC

12352005

Hazard Statement

H302

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Others; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Levobunolol-hydrochloride.html

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C.[H]Cl

Molecular Formula

C17H26ClNO3

Molecular Weight

327.85

Precautions

H302

References & Citations

[1]Mohammadi M, et al. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery. Acta Biomater. 2018 Jun;73:90-102.|[2]Kumar, N, et al. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. Futur J Pharm Sci 6, 109 (2020) .|[3]Zhang M, et al. Superior oblique myokymia treated with levobunolol. J AAPOS. 2018 Feb;22 (1) :67-69.e2.